• Earlier this week, IDEAYA Biosciences announced that it has begun Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892, a highly selective PRMT5 inhibitor for MTAP-deleted solid tumors including non-small cell lung cancer and pancreatic ductal adenocarcinoma, at exposures expected to provide 24‑hour EC90 target coverage.
• An interesting element of this update is IDEAYA’s plan to position IDE892 as a combination backbone across MTAP-deleted cancers, including collaborations with Roche’s pan‑RAS inhibitor and its own IDE397 and CDKN2A programs, in a setting where no approved therapies specifically target MTAP deletion.
• With IDE892 now in Part 2 monotherapy expansion, we will explore how its combination potential shapes IDEAYA’s broader investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

What Is IDEAYA Biosciences' Investment Narrative?

To own IDEAYA here, you really have to believe in its ability to convert a broad precision‑oncology platform into commercial products before the cash burn and current lack of profitability bite too hard. The big near-term focus still sits with darovasertib and other late-stage programs, but this week’s IDE892 Part 2 monotherapy expansion subtly reshapes the story: it reinforces the MTAP-deletion franchise as a potential second pillar, while also adding execution and clinical complexity. With IDE892 combinations lined up with IDE397, Roche’s pan‑RAS inhibitor and a future CDKN2A asset, the upside case leans on successful multi-drug development in an area where no MTAP-targeted therapies exist yet. The flip side is that IDEAYA remains loss-making, spending aggressively, and juggling a crowded early pipeline.

However, the growing MTAP platform also magnifies a risk many IDEAYA shareholders may be underestimating. IDEAYA Biosciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

You can see how widely opinions differ in the Simply Wall St Community, where three fair value estimates span from about US$53.54 up to a very large US$617.80 per share. Set that against the current story, where IDEAYA’s expanding MTAP combination agenda and ongoing losses keep execution risk front and center, and it becomes clear why it helps to review several of these viewpoints before deciding what the IDE892 update really means for the company’s longer term trajectory.

Explore 3 other fair value estimates on IDEAYA Biosciences - why the stock might be a potential multi-bagger!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your IDEAYA Biosciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IDEAYA Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEAYA Biosciences' overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.